Guangzhou Cellgene Biotech

Guangzhou Cellgene Biotech is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of next-generation cell therapies for oncology. The company leverages its proprietary cell engineering platforms to design advanced CAR-T and CAR-NK cell products aimed at treating both hematological malignancies and solid tumors. Cellgene Biotech focuses on addressing the limitations of current immunotherapies by enhancing cell persistence and developing off-the-shelf allogeneic solutions. Its lead program, a CD19-targeted CAR-T therapy, is currently undergoing clinical evaluation in China. The company is supported by a team of experts in immunology and has established state-of-the-art R&D and GMP manufacturing facilities to accelerate its pipeline development.